Abrégé

The present invention addresses the problem of providing a technique for improving the antibody-inducing ability of a nasal vaccine, and a composition for nasal administration having improved antibody-inducing ability. The problem is solved by a composition for nasal administration containing: at least one substance selected from the group consisting of antigen polypeptides and polynucleotides including a coding sequence of an antigen polypeptide; and a sugar component that is a sugar and/or a sugar alcohol, wherein the content of the sugar component is more than 4.5% by mass/volume.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 9/10 - DispersionsÉmulsions
• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 35/761 - Adénovirus
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 31/04 - Agents antibactériens
• A61P 31/10 - Antifongiques
• A61P 31/12 - Antiviraux
• A61P 33/00 - Agents antiparasitaires
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention relates to a composition for use in vaccines, the composition containing a cationic lipid represented by formula (1).

Classes IPC  ?

• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The present invention can provide an Enterovirus-derived VLP vaccine that is safe and has a high stability. The VLP vaccine of the present invention is safe because of using, as an antigen, VLPs free from internal genes of the virus. The VLP vaccine has a high safety because of being fixed in formaldehyde at a high salt concentration.

Classes IPC  ?

• A61K 39/125 - Picornaviridae, p. ex. calicivirus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/06 - Inactivation ou atténuationProduction de parties élémentaires de virus par traitement chimique

Abrégé

The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine.　Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus, in which the G protein does not have a modified sugar chain of a mammalian cell-expressed type.

Classes IPC  ?

• A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
• A61K 9/08 - Solutions
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 14/08 - Virus à ARN
• C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p. ex. contenant des motifs CpG
• C12N 15/40 - Protéines de virus à ARN, p. ex. flavivirus

Abrégé

The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. The present invention contains the fusion protein, which includes hemagglutinin and a receptor binding domain of SARS-CoV-2, and a vaccine containing the fusion protein.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

This fusion protein contains a plurality of receptor binding domains from parvovirus, wherein each receptor binding domain is tandemly linked with another such receptor binding domain, either directly or via a peptide linker.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/23 - Parvoviridae, p. ex. virus de l'aleucémie féline
• A61P 31/12 - Antiviraux
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07K 14/015 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
• C07K 19/00 - Peptides hybrides
• C12N 15/35 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

Provided is a strain that is effective as an active ingredient of a vaccine against betacoronavirus. This SARS-CoV-2 includes non-structural protein(s) that has the following responsible mutation(s): a mutation in the amino acid residue corresponding to the L of position 445 of SEQ ID NO: 1 in NSP3; a mutation in the amino acid residues corresponding to the G of position 248 and the G of position 416 of SEQ ID NO: 2 in NSP14; and/or a mutation in the amino acid residue corresponding to the V of position 67 of SEQ ID NO: 3 in NSP16.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 9/10 - Transférases (2.)
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Strains that is effective as the active component of a vaccine against the betacoronavirus is provided. A SARS-CoV-2 containing structural protein(s) and/or non-structural protein(s) having the following mutation(s): the amino acid residue mutations in NSP3, corresponding to V at position 404, L at position 445, K at position 1792 and/or D at position 1832 in SEQ ID No. 1; the amino acid residue mutations in NSP14, corresponding to G at position 248, G at position 416, and/or A at position 504 in SEQ ID No. 2; the amino acid residue mutation in NSP16, corresponding to V at position 67 in SEQ ID No. 3; the amino acid residue mutations in the spike, corresponding to L at position 54, T at position 739 and/or A at position 879 in SEQ ID No. 4; the amino acid residue mutation in the envelope, corresponding to L at position 28 in SEQ ID No. 5; and/or, the amino acid residue mutation in the nucleocapsid, corresponding to S at position 2 in SEQ ID No. 6;

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention provides a fusion protein which is useful as a vaccine antigen against infectious diseases. A fusion protein according to the present invention, including (a) a combination of hemagglutinin and an N-terminal domain of SARS-CoV-2, (b) a combination of PspA and a receptor binding domain of SARS-CoV-2, (c) a combination of hemagglutinin and respiratory syncytial virus G protein, or (d) a combination of PspA and hemagglutinin, is useful as a vaccine antigen against infectious diseases.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/02 - Antigènes bactériens
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/04 - Agents antibactériens
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza
• C07K 14/135 - Virus respiratoire syncytial
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• C07K 19/00 - Peptides hybrides
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
• C12N 15/44 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

To provide an adjuvant containing lipid particles having a higher immune response inducing ability (preferably, Th1-type immune response inducing ability). This adjuvant contains lipid particles containing a cationic lipid represented by general formula (1).

Classes IPC  ?

• A61K 31/14 - Composés d'ammonium quaternaire, p. ex. édrophonium, choline
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61P 37/04 - Immunostimulants

Abrégé

The purpose of the present invention is to provide a strain that is useful as a new betacoronavirus vaccine. A novel betacoronavirus, according to the present invention, having, in combination, a prescribed substitution mutation relating to temperature sensitivity, and a prescribed deletion mutation relating to attenuation, is found to be useful as a betacoronavirus vaccine strain having excellent attenuated characteristics.

Classes IPC  ?

• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 37/04 - Immunostimulants
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible

Abrégé

The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. This fusion protein includes hemagglutinin and a receptor binding domain of SARS-CoV-2. This vaccine includes said fusion protein.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)

Abrégé

A strain that is effective as the active component of a vaccine against the beta coronavirus is provided. A SARS-CoV-2 virus containing a structural protein and/or nonstructural protein having the following mutations: the amino acid residue mutation in NSP3, corresponding to V at position 404, L at position 445, K at position 1792 and/or D at position 1832 in SEQ ID No. 1; the amino acid residue mutation in NSP14, corresponding to G at position 248, G at position 416, and/or A at position 504 in SEQ ID No. 2; the amino acid residue mutation in NSP16, corresponding to V at position 67 in SEQ ID No. 3; the amino acid residue mutation in the spike, corresponding to L at position 54, T at position 739 and/or A at position 879 in SEQ ID No. 4; the amino acid residue mutation in the envelope, corresponding to L at position 28 in SEQ ID No. 5; and/or, the amino acid residue mutation in the nucleocapsid, corresponding to S at position 2 in SEQ ID No. 6;

Classes IPC  ?

• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/12 - Antiviraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 37/04 - Immunostimulants
• C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 7/08 - Inactivation ou atténuationProduction de parties élémentaires de virus par passages successifs de virus
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étrangerProcédés de criblage à cet effet
• C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
• C12N 15/55 - Hydrolases (3)
• C12Q 1/6869 - Méthodes de séquençage

Abrégé

Provided is a strain that is effective as an active ingredient of a vaccine against a betacoronavirus. This SARS-CoV-2 virus includes a non-structural protein that has the following responsible mutation(s): a mutation in the amino acid residue corresponding to the L of position 445 of SEQ ID NO: 1 in NSP3; a mutation in the amino acid residues corresponding to the G of position 248 and the G of position 416 of SEQ ID NO: 2 in NSP14; and/or a mutation in the amino acid residue corresponding to the V of position 67 of SEQ ID NO: 3 in NSP16.

Classes IPC  ?

• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/12 - Antiviraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 37/04 - Immunostimulants
• C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 7/08 - Inactivation ou atténuationProduction de parties élémentaires de virus par passages successifs de virus
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étrangerProcédés de criblage à cet effet
• C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
• C12N 15/55 - Hydrolases (3)
• C12Q 1/6869 - Méthodes de séquençage

Abrégé

The present invention provides a corona virus that has restricted replication characteristics, in that it cannot replicate in normal host cells but can replicate in special host cells. The knockout coronavirus has lost at least some of the function of a replication-related gene on the coronavirus genomic RNA, and is unable to replicate in a host cell that lacks the replication-related gene while having the capacity to replicate in a host cell that contains the replication-related gene.

Classes IPC  ?

• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 37/04 - Immunostimulants
• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

The present invention addresses the problem of providing a preventive agent for Japanese encephalitis and a Japanese encephalitis vaccine that are capable of giving humans adequate immunity even with a dose smaller than that for a subcutaneously-administered Japanese encephalitis vaccine or with fewer administrations as compared to the number of administrations of a subcutaneously-administered Japanese encephalitis vaccine. The present invention provides a preventive agent for Japanese encephalitis, which includes a microneedle array that comprises a sheet and a plurality of needles disposed on the top surface of said sheet, the needles being configured to either include or carry thereon inactivated Japanese encephalitis virus.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau

Abrégé

Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza

Abrégé

Provided is a production method for reassortant influenza virus having genome segments of two or more kinds of influenza virus in the case where an antigenic strain and donor strain have similar antigenicities. The production method makes use of the first influenza virus containing an antigenic protein, the second influenza virus having an antigenic protein having antigenicity similar to that of the strain, and the third influenza virus having an antigenic protein having antigenicity different from that of the strain, and includes the steps of: coculturing the strain and the strain by infecting a host therewith, to produce reassortant influenza viruses; selecting influenza virus having the antigenic protein from the viruses; then coculturing the strain and the selected strain by infecting a host therewith; and selecting influenza virus having the antigenic protein from reassortant influenza viruses produced from the strain and the strain.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial cell component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial cell component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.

Classes IPC  ?

• C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial cell component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial cell component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.

Classes IPC  ?

• C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

[Problem] To provide a CHO cell line for producing a viral structural protein having a higher-order structure. [Solution] A CHO cell line for producing a viral structural protein having a higher-order structure, said CHO cell line having an expression vector, which contains a gene encoding the structural protein and a promoter connected in an operable manner to the gene, introduced thereinto.

Classes IPC  ?

• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• C12N 15/35 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
• C12N 15/41 - Picornaviridae, p. ex. rhinovirus, virus coxsackie, échovirus, entérovirus
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The present invention addresses the problem of providing an antigen for generating an antibody for inhibiting infection of multiple types of HuNov, a use thereof, and an antibody for inhibiting infection of multiple types of HuNov. Specifically, the present invention provides: a method for producing an antibody for inhibiting infection of different genotypes of human norovirus (HuNoV) to intestinal epithelial cells, comprising immunization using the full length or a part of VP1 protein of GII.17 HuNoV as an antigen; and an antibody for inhibiting infection of a plurality of different genotypes of HuNoV to intestinal epithelial cells.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/12 - Antigènes viraux
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 15/13 - Immunoglobulines

Abrégé

Provided is a method for culturing the influenza virus using MDCK cells as a host, wherein the influenza virus is cultured more efficiently. The influenza virus is inoculated under protease-free medium conditions after the MDCK cells have passed the logarithmic growth phase. Aggregation and damage of MDCK cells by protease can be prevented, and the influenza virus can be cultured efficiently. In addition, a higher yield of viral protein is expected than when the influenza virus is grown using chicken eggs as the host.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

Problem: To provide a multi-layer culture vessel observation system, a carriage device and a multi-layer culture vessel observation device, with which it is possible for an operator to easily observe a to-be-observed object in a multi-layer culture vessel. Solution: A multi-layer culture vessel observation system comprising: a movable carriage device 20 in which a multi-layer culture vessel 30 having a plurality of built-in trays is installed; and an observation device 10 which allows a to-be-observed object in the trays of the multi-layer culture vessel 30 to be observed, wherein: the carriage device 20 includes a frame comprising a side surface exposure part which exposes, from top to bottom, two side surfaces faced by the multi-layer culture vessel 30; the observation device 10 includes an accommodation part 14 which accommodates the carriage device 20 with the multi-layer culture vessel 30 installed therein, and an image pick-up device 11 which comprises an optical system and outputs an image formed by said optical system; and when the carriage device 20 in which the multi-layer culture vessel 30 is installed is accommodated in the accommodation part 14, the side surface exposure part is positioned on the optical axis of the image pick-up device 11.

Classes IPC  ?

• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu

Abrégé

The present invention provides a substance which is useful as a carrier for protein purification. Since an aluminum phosphate compound that is obtained by a method for producing an aluminum phosphate compound, which comprises a step for obtaining a mixture that contains an aluminum phosphate compound by mixing an aqueous solution A containing phosphate ions with an aqueous solution B containing aluminum ions, sulfate ions and at least either potassium ions or magnesium ions, exhibits excellent protein adsorption properties, this aluminum phosphate compound is useful as a carrier for protein purification.

Classes IPC  ?

• C01B 25/36 - Phosphates d'aluminium
• B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/30 - Procédés de préparation, de régénération ou de réactivation

Abrégé

The present invention addresses the problem of providing a Japanese-encephalitis-vaccine-containing microneedle array in which it is possible to suppress a decrease in the activity of the Japanese encephalitis vaccine during production of a microneedle array. The present invention provides a microneedle array having a sheet part and a plurality of needle parts present on the upper surface of the sheet part, wherein: the needle parts contain an electrically neutral water-soluble polymer and/or disaccharide, Japanese encephalitis vaccine, and an electrically neutral surfactant; and the sheet part contains an electrically neutral water-soluble polymer and/or disaccharide.

Classes IPC  ?

• A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau

Abrégé

The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• C07K 14/36 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant d'ActinomycesPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptomyces (G)
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• C07K 19/00 - Peptides hybrides
• A61P 37/04 - Immunostimulants
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

in vitroin vitro, the method avoiding the moral issues involved with conventional methods and the need to treat cells with bile. Specifically, the present invention relates to: a method for proliferating HuNoV, the method including a step for infecting an intestinal epithelial cell derived from a human iPS cell with HuNoV, and a step for culturing said intestinal epithelial cell; and a screening method for a HuNoV-proliferation inhibitor using said method.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention provides a vaccine for enteroviruses. In view of the structure of enteroviruses, particularly VP0's cleaving VP2 and VP4, it was discovered that said cleaving affects immunogenicity. In other words, it is believed that designing a vaccine including a large amount of VP2 and VP4 as polypeptides which exhibit immunogenicity leads to providing a vaccine which exhibits high immunogenicity. Polypeptides including VP1, VP2, VP3, and VP4 derived from an enterovirus are produced, and these polypeptides are confirmed to have a high effect as an immunogen against enteroviruses.

Classes IPC  ?

• C07K 14/085 - Picornaviridae, p. ex. virus coxsackie, échovirus, entérovirus
• A61K 39/125 - Picornaviridae, p. ex. calicivirus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 9/50 - Protéinases

Abrégé

Provided is a method for constructing a reassortant influenza virus that has genomic segments of at least two types of influenza virus when an antigen strain and a donor strain have analogous antigenicity. The method relies upon a step for using (1) a first influenza virus containing an antigen protein (x), (2) a second influenza virus containing an antigen protein (x') having antigenicity analogous to that of strain (1), and (3) a third influenza virus containing an antigen protein (y) having antigenicity different from that of strain (1) to infect hosts with strain (2) and strain (3) and co-culture to construct reassortant influenza viruses, and selecting an influenza virus (Y) comprising the antigen protein (y) from among said viruses, followed by infecting hosts with strain (1) and the selected strain (Y), co-culturing, and selecting an influenza virus (X) comprising the antigen protein (x) from the reassortant influenza viruses constructed from strain (1) and strain (Y).

Classes IPC  ?

• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger

Abrégé

Provided is a method whereby a sterilized viscous base can be easily produced at a high sterilization efficiency. The method for producing a sterilized viscous base (base no. 5) comprises: a heat sterilization step for heat sterilizing an acidic solution of a viscosity-imparting agent (base no. 2) which shows a higher viscosity in a neutral range than in an acidic range; and a neutralization step for, after the heat sterilization step, neutralizing the heat sterilized product (base no. 3) of the acidic solution of the viscosity-imparting agent by adding a base thereto.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61P 37/04 - Immunostimulants

Abrégé

The present invention addresses the problem of providing a polyvalent vaccine that is capable of inducing immunity against two or more kinds of microorganisms including Clostridium perfringens and also providing a medicinal composition that is capable of efficiently preventing and/or treating infectious disorders. To solve this problem, provided is a polyvalent vaccine characterized by comprising, as active ingredients, a C-terminal fragment of C. perfringens enterotoxin (C-CPE) and at least one antigen derived from a microorganism other than C. perfringens and being capable of inducing immunity against two or more kinds of microorganisms including C. perfringens. In the polyvalent vaccine according to the present invention, the C-CPE and the at least one antigen form together a fusion so that the capability of inducing immunity against two or more kinds of microorganisms including C. perfringens can be exerted.

Classes IPC  ?

• A61K 39/116 - Antigènes bactériens polyvalents
• A61K 39/08 - Clostridium, p. ex. Clostridium tetani
• A61K 39/106 - VibrioCampylobacter
• A61K 39/108 - EscherichiaKlebsiella
• A61P 37/04 - Immunostimulants

Abrégé

Provided is lipid A, which has a novel structure. More specifically, provided is lipid A which can be used in an adjuvant, and with which side effects such as allergic reaction and inflammation are reduced, while maintaining an excellent immunological activation ability. Also provided is an adjuvant composition including lipid A. Lipid A is characterized by comprising a complex of a glucosamine disaccharide chain and fatty acid chains. Lipid A is further characterized in that: 3-hydroxy fatty acid chains are bonded to positions 2 and 2' of the glucosamine disaccharide chain; and a secondary fatty acid chain comprising a 3-hydroxy fatty acid chain is further bonded to at least one of the 3-hydroxy fatty acid chains. The adjuvant including lipid A inhibits side effects such as allergic reaction and inflammation, while maintaining excellent immunological activation action in comparison to adjuvants known in the prior art.

Classes IPC  ?

• C12P 19/00 - Préparation de composés contenant des radicaux saccharide
• A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants
• C07H 13/06 - Acides gras

Produits et services

Pharmaceutical preparations; biological preparations for medical purposes; vaccines.

Produits et services

Pharmaceutical preparations; biological preparations for medical purposes; vaccines.

Abrégé

The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
• A61P 37/04 - Immunostimulants
• C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
• C07K 19/00 - Peptides hybrides
• C12N 15/09 - Technologie d'ADN recombinant
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

The purpose of the present invention is to provide: an adjuvant composition which is highly safe and can effectively improve a protective immunity induced by a vaccine; and a vaccine preparation utilizing the adjuvant composition. A CpG oligodeoxynucleotide is selected among from adjuvants, and the CpG oligodeoxynucleotide is used in combination with carbonate apatite. The adjuvant composition is highly safe and can effectively improve a protective immunity induced by a vaccine.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 47/04 - Non-métauxLeurs composés
• A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif

Abrégé

Provided is a method for producing a reassortant influenza virus having genome segments from two or more influenza virus strains. This method for producing a reassortant influenza virus containing an antigen protein from a first influenza virus strain comprises the following steps: 1) A step in which the first influenza virus strain is irradiated with ultraviolet rays at a dose at which the virus has reduced or no proliferation capacity and maintains initial infectivity; 2) a step in which a host is infected with the first influenza virus strain and a second influenza virus strain; 3) a step in which the host infected with the first influenza virus strain and the second influenza virus strain is cultured to obtain a culture; 4) a step in which, from the culture obtained at step 3), an influenza virus strain having an antigen protein of the second influenza virus strain is deactivated; and 5) a step in which a reassortant influenza virus is recovered following step 4).

Classes IPC  ?

• C12N 7/02 - Isolement ou purification
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza

Abrégé

The present invention pertains to: cloned MDCK cells which exhibit an expansion factor of 4.5-fold or more when being cultured using microcarriers; a method for culturing the MDCK cells; and a method for multiplying a virus by using the MDCK cell culturing method.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The present invention relates to a purification method for target protein, using a layered double hydroxide represented by general formula (I) below. General formula (I): [M2+1-xM3+x(OH)2][An-x/n・mH2O] (In general formula (I) above: M2+ and M3+ are a divalent metal and a trivalent metal, respectively; An- is an interlayer anion; x is given by [M3+]/（[M2+]＋[M3+]; and x is 0.1-0.9, n is 1-3, and m is 0-100).

Classes IPC  ?

• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 37/04 - Immunostimulants
• B01D 15/04 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solidesAppareillages pour ces procédés par des substances échangeuses d'ions comme adsorbants
• B01J 20/06 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe

Abrégé

Provided are: a vaccine pharmaceutical composition for oral administration, capable of stably storing an influenza virus antigen; and a method for manufacturing the pharmaceutical composition. The vaccine pharmaceutical composition for oral administration is characterized by containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/38 - CelluloseSes dérivés
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

The present invention pertains to a method for measuring complement-dependent bactericidal function with respect to pneumococci, and provides a method for measuring activity which can perform measurements with respect to all capsular serotypes of pneumococcus. This method employs the measurement of complement-dependent bactericidal function with respect to pneumococci, using capsule deleted pneumococci, that is to say noncapsular or close to noncapsular, or transparent pneumococci. With this method it is possible to measure complement-dependent bactericidal function with respect to all capsular serotypes of pneumococcus.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• G01N 33/15 - Préparations médicinales
• C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 5/078 - Cellules du sang ou du système immunitaire
• C12N 5/0787 - Granulocytes, p. ex. basophiles, éosinophiles, neutrophiles ou mastocytes

Abrégé

Provided is an antigen composition, pertaining to human herpes virus 6B (HHV-6B), which can be stably supplied in a large amount. Also provided is a vaccine including this antigen composition. Also provided is a method for producing this antigen composition. HHV-6B antigen tetrameric complexes including gH, gL, gQ1, and gQ2 among the surface proteins of HHV-6B are used as the antigen composition. The HHV-6B antigen tetrameric complexes make it possible to provide an antigen composition which can be stably supplied in a large amount. Because the antigen composition can be stably supplied in a large amount, it is possible to stably supply vaccines and pharmaceutical compositions including this antigen composition, which is industrially advantageous.

Classes IPC  ?

• C07K 14/03 - Herpetoviridae, p. ex. virus de la pseudorage
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/245 - Herpetoviridae, p. ex. virus de l'Herpès simplex
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
• A61P 37/04 - Immunostimulants
• C07K 19/00 - Peptides hybrides
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

The invention pertains to MDCK cells that can be used suitably in influenza virus production. In particular, it pertains to MDCK cells for influenza virus production having excellent influenza virus production efficiency without coculture with other species of cells. It also pertains to a method for producing an influenza virus characterized by using these MDCK cells.

Classes IPC  ?

• C12N 5/07 - Cellules animales ou tissus animaux
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The present invention relates to an adjuvant, which is a layered double hydroxide and is obtained from a compound represented by general formula (I) in the Specification. Because the layered double hydroxides in the present invention are conjugates with an inorganic ion selected from light metals, it is thought that adverse reactions of a living body when an immune composition comprising an adjuvant according to the present invention is administered to the living body will be minimal. Because there are countless combinations of divalent cations, trivalent cations and anions in layered double hydroxides, it is possible to manufacture a layered double hydroxide suited to the use thereof.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/05 - CorynebacteriumPropionibacterium
• A61K 39/08 - Clostridium, p. ex. Clostridium tetani
• A61K 39/09 - Streptococcus
• A61K 39/10 - BrucellaBordetella, p. ex. Bordetella pertussis
• A61K 39/12 - Antigènes viraux
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/29 - Virus de l'hépatite
• A61P 31/04 - Agents antibactériens
• A61P 31/12 - Antiviraux
• A61P 37/04 - Immunostimulants

Abrégé

　The purpose of the present invention is to provide a novel antibody having high avidity and high neutralizing activity with respect to an influenza virus. The present invention provides an antibody for neutralizing the H1-type influenza virus and/or the H5-type influenza virus, which have: a heavy chain variable region having a CDR composed of a specific heavy chain first complementarity determining region (VH-CDR1), a heavy chain second complementarity determining region (VH-CDR2), and a heavy chain third complementarity determining region (VH-CDR3); and a light chain variable region having a CDR composed of a specific light chain second complementarity determining region (VL-CDR2), and a light chain third complementarity determining region (VL-CDR3).

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/08 - Anticorps monoclonaux

Abrégé

Materials and methods are provided for detecting, preventing, and treating dengue virus infections and symptoms. Antigenic peptides, isolated nucleic acids encoding such peptides, reagents containing such peptides, reagent kits, and method of detections are provided. Vaccines are provided that contain one or more antigenic peptides based on the first domain II of a dengue virus (DENV) envelope protein (EDII). These vaccines are capable of stimulating a dengue virus immunological response in a subject previously infected with a dengue virus. Methods of manufacturing such vaccines are also presented. Further provided are methods of administering such vaccines to vaccinate a subject that has or has not been previously infected with a dengue virus.

Classes IPC  ?

• C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by lowpH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HAl and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C12N 15/02 - Préparation de cellules hybrides par fusion de plusieurs cellules, p. ex. fusion de protoplastes
• C12P 21/08 - Anticorps monoclonaux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

Materials and methods are provided for treating dengue infections. Human monoclonal antibodies against all serotypes of dengue virus are also provided. Methods of using human monoclonal antibodies to neutralize all dengue-virus serotypes are provided using patients' peripheral blood lymphocytes.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The present invention addresses the problem of providing a vaccine which as yet has not been provided for the disease HHV-6B, which is the cause of exanthema subitum in infants, and the problem of providing an effective screening method for other therapeutic drugs. The above-mentioned problems are solved by providing an epitope specific to HHV-6B, wherein, of the amino acid sequence (QALCEGGHVFYNP) represented by positions 484 to 496 of SEQ ID NO: 2 or a modified sequence thereof, the epitope either has a sequence comprising at least five consecutive amino acids including at least E, or a sequence that preserves the 487th C and 489th G when E is changed to Q.

Classes IPC  ?

• C07K 14/03 - Herpetoviridae, p. ex. virus de la pseudorage
• A61K 39/245 - Herpetoviridae, p. ex. virus de l'Herpès simplex
• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
• C12N 15/09 - Technologie d'ADN recombinant
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Abrégé

Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention provides an anti-influenza virus antibody that has neutralizing activity against any of the influenza viruses which are categorized into two groups by degree of amino acid conservation in hemagglutinin, regardless of any differences between the groups. The present invention also provides a method for producing the same, and a method for testing whether a subject has the neutralizing antibody.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The present invention addresses the problem of establishing a method for predicting onset risk of herpes zoster against which the acquisition or lack of immunity can be exclusively examined so far. A method for predicting the onset risk of herpes zoster in future which comprises employing, as a standard, at least one factor selected from among the major diameter of an edema, the outer circumferential length of an erythema and the average erythema diameter.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Produits et services

Pharmaceutical, veterinary and sanitary preparations, other than pyrethrum coils and other anti-mosquito incenses and fragrances, medicated soaps of Japanese pharmacopoeia, and medicated alcoholic beverages.

Abrégé

Disclosed is an enhancer for a viral promoter such as a promoter that can induce expression selectively and strongly in immunocompetent cells (e.g., lymphocytes) or blood cells. It is found unexpectedly that an intron has the above-mentioned enhancer activity. Thus, it is found that an enhancer for a promoter, which comprises an intron sequence for a major immediate early gene (MIE) of human herpes virus-6 (HHV-6) (particularly HHV-6B) or a fragment of the intron sequence, has a potent promoter activity.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Produits et services

(1) Pharmaceutical, veterinary and sanitary preparations (other than pyrethrum coils and other anti-mosquito incenses and fragrances, and medicated soaps of Japanese Pharmacopoeia), namely human vaccines, veterinary vaccines, antibodies for biopharmaceutical purposes; biological preparations for treating Influenza, Japanese Encephalitis, Measles virus, Rubella virus, Varicella virus, human Papilloma virus, Diptheria, Tetanus and Pertussis.

Abrégé

Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP).

Classes IPC  ?

• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The present invention provides a vaccine composition for transnasal mucous membrane administration, which contains an influenza virus antigen, polyriboinosinic polyribocytidylic acid (poly (I:C)) or a derivative thereof and a carboxyvinyl polymer. The present invention also provides a prophylactic method of influenza, including a step of administering the vaccine composition at least once to the nasal mucosa of a subject in need thereof.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza

Abrégé

Disclosed is a human antibody having a neutralization activity against a human influenza virus. Specifically disclosed is a human antibody which can recognize a highly conserved region in a human influenza A virus subtype H3N2 and a human influenza B virus and has a neutralization activity against the virus. More specifically disclosed is a human anti-human influenza virus antibody which has a neutralization activity against a human influenza A virus subtype H3N2 and is capable of binding to a hemagglutinin HA1 domain in a human influenza A virus subtype H3N2 or which has a neutralization activity against a human influenza B virus, wherein the nucleotide sequence of DNA that encodes a variable region of the antibody comprises any one sequence selected from those depicted in SEQ ID NO:5 to SEQ ID NO:12.

Classes IPC  ?

• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

Disclosed are: a signal peptide for secreting/producing a virus-like particle (VLP) at a high level, which comprises a modified product of a signal sequence derived from a West Nile virus (WNV); an expression vector for secreting a WNV VLP, which comprises a nucleic acid encoding the signal peptide, a nucleic acid encoding prM protein and a nucleic acid encoding E protein; an animal cell line capable of secreting/producing a WNV VLP at a high level, which has the vector introduced therein; a WNV vaccine comprising, as an active ingredient, a WNV VLP produced by using the cell line; and a WNV DNA vaccine comprising, as an active ingredient, the expression vector for secreting the VLP.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 39/12 - Antigènes viraux
• A61P 31/12 - Antiviraux
• C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

Disclosed are a cancer antigen peptide vaccine and an adjuvant for a virus antigen peptide, each of which comprises a pertussis vaccine as the main ingredient. Also disclosed is an agent for the treatment of cancer or a viral infection or for the prevention of the metastasis or recurrence of cancer or a virus-induced tumor, which comprises a cancer antigen peptide or a virus antigen peptide and a pertussis vaccine. A whole cell pertussis vaccine can be particularly preferably used as the pertussis vaccine. The agent is safe for multiple times of administration.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/12 - Antigènes viraux
• A61K 39/29 - Virus de l'hépatite
• A61P 31/12 - Antiviraux
• A61P 35/00 - Agents anticancéreux
• C07K 14/235 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bordetella (G)
• C07K 14/82 - Produits de traduction des oncogènes

Abrégé

It is intended to contribute to the elucidation of the mechanism of postzoster neuralgia and to provide means for promoting the regeneration of damaged nerve. Further, it is intended to provide means which is effective in the prevention or treatment of a disorder caused by neuronal cell death accompanying postzoster neuralgia, chronic pain, postherpetic neuralgia, apoplexy, a degenerative disease or the like, or any of the above diseases, and has fewer side effects. A neurite elongation promoter comprising an antibody that recognizes a varicella-zoster virus immediate-early protein and crossreacts with a brain-derived neurotrophic factor as an active ingredient; a preventive or therapeutic agent for a neurogenic disease comprising the antibody as an active ingredient; a neurite elongation inhibitor comprising an inhibitory antibody that recognizes a varicella-zoster virus immediate-early protein and inhibits a brain-derived neurotrophic factor as an active ingredient; and a preventive or therapeutic agent for a disease accompanied by neural hypersensitivity caused by a condition selected from the group consisting of postzoster neuralgia, chronic pain, experience-dependent social aversion and stress, comprising the inhibitory antibody as an active ingredient.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 21/04 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire de la myasthénie
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
• A61P 25/16 - Antiparkinsoniens
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
• A61P 35/00 - Agents anticancéreux
• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus

Abrégé

To supply an influenza vaccine having an enhanced effect, it is intended to provide an adjuvant which enables the potentiation of both of humoral immunity and cellular immunity, and an influenza vaccine using the same. As a means for resolution, an adjuvant for an influenza vaccine which comprises biodegradable nanoparticles having a polyamino acid as the skeleton thereof and an influenza vaccine which contains an influenza virus antigen and the adjuvant as described above are provided. As the polyamino acid, one having poly(γ-polyglutamic acid) as the main constituent is preferred.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Disclosed are: a precipitated/inactivated whole virus influenza vaccine which can effectively act on a new-type influenza virus, particularly a new-type virus having low immunogenicity, at a low amount of antigen and which has little adverse side-effects; and a method for producing the vaccine. Specifically disclosed are: a precipitated/inactivated influenza vaccine comprising an aluminum hydroxide gel prepared from sodium carbonate and aluminum potassium sulfate and an isolated whole influenza virus particle as active ingredients; and a method for producing the precipitated/inactivated influenza vaccine, which is characterized by conducting each step by using a solvent containing no surfactant or no ether.

Classes IPC  ?

• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Disclosed are recombinant varicella-zoster virus, a process for producing the virus, a pharmaceutical composition comprising the recombinant varicella-zoster virus, a vector having a BAC vector sequence in a specific gene of the varicella-zoster virus genomic gene, a cell having the vector therein, a fragment capable of homologous recombination with the varicella-zoster virus genome, a nucleic acid cassette comprising a BAC vector sequence, and a polyvalent vaccine. A process for producing a recombinant varicella-zoster virus having a BAC vector sequence inserted in a specific viral gene.

Classes IPC  ?

• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• A61K 39/25 - Herpesvirus varicellae
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
• A61P 37/04 - Immunostimulants
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion

Abrégé

A therapeutic agent for cancer comprising, as an active ingredient, a substance capable of binding to HB-EGF to thereby inhibit the binding between HB-EGF and an EGF receptor (particularly CRM197), the cancer being selected from the group consisting of bladder cancer, colorectal cancer or disseminated peritoneal metastatic cancer from gastric cancer and pancreatic cancer.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Produits et services

(1) Pharmaceutical preparations, diagnostic preparations and biological products for human and animal use, namely: rubella vaccine, influenza vaccine, mumps vaccine, cholera vaccine, diphtheria antitoxin, diptheria toxoid, mixed diphtheria/tetanus toxoid, smallpox vaccine, Japanese encephalitis vaccine, tetanus antitoxin, tetanus toxoid, mixed pertussis/diphtheria vaccine, mixed pertussis/diphtheria/tetanus vaccine, measles vaccine, agkistrodon antitoxin, pertussis vaccine, measles virus antigen for diagnosis, Japanese encephalitis virus antigen for diagnosis, rubella virus antigen for diagnosis, mumps virus antigen for diagnosis, complement, typhys vaccine, equine antiserum against human serum, hemolysin, varicella vaccine, mixed measles/mumps/rubella vaccine, hepatitis B vaccine, varicella antigen, marek's disease vaccine, porcine parvovirus vaccine, gumboro disease vaccine, acquired immunodeficiency syndrome vaccine, human immunodeficiency virus antigen for diagnosis, non-A, non-B hepatitis vaccine, non-A, non-B hepatitis antigen for diagnosis, non-A, non-B hepatitis DNA probe for diagnosis, hemorrhagic fever with renal syndrome virus vaccine, hemorrhagic fever with renal syndrome virus antigen for diagnosis.